Table 3.
The characteristics of research participants in the validation phase
| Variable | Healthy (n = 63) | HBV carrier (n = 32) | CHB (n = 28) | LC (n = 114) |
P-value¹ | P-value² | |||
|---|---|---|---|---|---|---|---|---|---|
| All (n = 114) | CP-A (n = 49) | CP-B (n = 34) | CP-C (n = 31) | ||||||
| Age, years | 34.8 ± 14.8 | 37.5 ± 8.7 | 38.4 ± 11.4 | 50.1 ± 11.7 | 49.9 ± 10.4 | 52.2 ± 11.9 | 48.3 ± 13.3 | <0.001 | <0.001 |
| Female gender | 35 (55.6) | 9 (28.1) | 9 (32.1) | 28 (24.6) | 11 (22.4) | 10 (29.4) | 7 (22.6) | <0.001 | 0.023 |
| WBC, × 109/L | 6.4 ± 1.5 | 6.5 ± 1.6 | 6.3 ± 1.5 | 4.6 ± 2.2 | 4.9 ± 2.4 | 3.9 ± 1.8 | 4.7 ± 2.4 | <0.001 | <0.001 |
| ALT, U/L | 16.0 [11.5–24.0] | 31.5 [23.8–46.0] | 208.0 [74.0–560.8] | 28.0 [21.0–37.8] | 28.0 [21.3–37.0] | 27.0 [21.0–33.3] | 32.5 [18.8–98.0] | <0.001 | <0.001 |
| Serum albumin | <0.001 | <0.001 | |||||||
| >35 g/L | 16 (100.0) | 26 (100.0) | 13 (56.5) | 60 (52.6) | 44 (89.8) | 10 (29.4) | 6 (19.4) | ||
| 28–35 g/L | 0 | 0 | 9 (39.1) | 47 (41.2) | 5 (10.2) | 24 (70.6) | 18 (58.1) | ||
| <28 g/L | 0 | 0 | 1 (4.3) | 7 (6.1) | 0 | 0 | 7 (22.6) | ||
| Total bilirubin | <0.001 | <0.001 | |||||||
| >51 µmol/L | 0 | 3 (10.3) | 20 (90.9) | 32 (28.1) | 0 | 5 (14.7) | 27 (87.1) | ||
| 34–51 µmol/L | 0 | 0 | 1 (4.5) | 14 (12.3) | 3 (6.1) | 9 (26.5) | 2 (6.5) | ||
| <34 µmol/L | 12 (100.0) | 26 (89.7) | 1 (4.5) | 68 (59.6) | 46 (93.9) | 20 (58.8) | 2 (6.5) | ||
Values presented as mean ± standard deviation, median [interquartile range], or n (%).
HBV, hepatitis B virus; CHB, chronic hepatitis B; LC, liver cirrhosis; CP, Child–Pugh classification; SD, standard deviation; WBC, white blood cell; ALT, alanine aminotransferase.
P-value1 = comparison among Healthy, HBV carrier, CHB, and LC groups.
P-value2 = comparison among Healthy, HBV carrier, CHB, LC CP-A, LC CP-B, and LC CP-C groups.